Minimize

Welcome!

Theralase PDT Technology Used to Treat First Patient for Bladder Cancer

Cory
April 4, 2017

Here is the news a lot of people (including us) were waiting for. Theralase has enrolled and treated its first patent just last week and the other two patients are also enrolled.

We will be chatting with Roger later this week for a full update. Please email or comment with your questions.

Click here to visit the Theralase website.

Here is the news.

Toronto, Ontario – April 4, 2017, Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the first patient was treated on March 30, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology.

The PDT treatment procedure involves the instillation of a water based solution of Theralase’s lead anti-cancer PDC, TLD-1433, through the urethra into the bladder of the patient, to allow localization of the PDC to the NMIBC. The bladder is then drained of the solution, flushed with sterile water to remove excess solution and refilled with sterile water via a cystoscope. At this point, a fibre optic assembly, with the ability to both emit and detect laser light, is inserted through the cystoscope, to activate the PDC.

The Phase Ib NMIBC clinical study (“Study”) will be used to evaluate TLD-1433 for the primary endpoints of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.

The Study has been designed to treat 3 patients at a lower dose of the PDC and to monitor the patients for 30 days, according to the endpoint criteria above. If successful, then an additional 6 patients will be enrolled into the Study to be treated at a higher dose of the PDC and monitored for 180 days, according to the endpoint criteria.

The next 2 patients in the Study have been enrolled and are currently scheduled for treatment.

Roger Dumoulin-White, President and CEO of Theralase stated that, “This is the first time that the Company’s PDT technology has been used in human clinical testing and represents a major milestone achievement for the Company, significantly de-risking the Company by shifting it from a pre-clinical to now a clinical biotech organization in oncology.

Theralase looks forward to successfully treating the next 2 patients and reporting out on the status of the first three patients in the Study in 2Q2017.”

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology (“TLT”) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT”) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs”), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com .

This news release contains “forward-looking statements” which reflect the current expectations of management of the Corporation’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the proposed use of proceeds. Wherever possible, words such as “may”, “would”, “could”, “should”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Corporation’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Corporation with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Corporation cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The C orporation disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & CEO

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225

rwhite@theralase.com

www.theralase.com

Discussion
16 Comments
    Apr 04, 2017 04:42 AM

    Great news. Pass it around. Don’t let the AMA smash price.l

    Apr 04, 2017 04:37 AM

    Very happy to see this. Good luck to all involved, shareholders and patients!

    Apr 04, 2017 04:35 PM

    pump, Pump, PUMP it up! I am averaged in at 0.275 with just over $1000 principle invested.

    Apr 04, 2017 04:48 PM

    OK some expert: 2 cent move. Why not $1 or $2. I s the Market Maker suppressing the price? What is going on here?

      Apr 05, 2017 05:55 PM

      I bet if the Market Maker were asked questions about what business TLTFF was in and what did their last Press Release say, he wouldn’t have a clue.

    Apr 04, 2017 04:01 PM

    What can shareholders expect in connection to news flow regarding this bladder trial and ask for an update on brain cancer indication.

      Apr 05, 2017 05:31 AM

      Dr.Mandel Oct 28/2016 said in 6 months to have a Ph 1b outline done.. thats’ April 28 2017 roughly speaking + few days for holidays.

    Apr 04, 2017 04:39 PM

    nice news but what about the super kicker of immunity as i understand they injected the animals with “colon” cancer and made the discovery fairly quickly how about humans time frame

      Apr 06, 2017 06:45 AM

      First things first terry. Natural immunity that may occur post-treatment may take many months and dozens if not hundreds of treatments to show statistical evidence that immunity has been imparted. It isn’t like they can just take a blood test and say “look they are immune!”

        Apr 06, 2017 06:54 AM

        thanks jj i was curious about time frame as chances of infecting humans seemed pretty remote

    Apr 05, 2017 05:29 AM

    Please ask how much cash is in the coffers? Runway?

    Please update us since last on the uplisting procedures started by Al and Roger, those papers have to be done by now. It’s been close to a year.

    If the 30 day CT tissue shows all clear and theres no organ damage like photofrin showed… we win.

      Apr 06, 2017 06:47 AM

      We should have a slightly better view of that when they file YE results at the end of the month. Revs from the therapeutic laser division would help slow the burn rate.

    Apr 06, 2017 06:51 AM

    I would like to hear that the first patient was treated and how the DFOC cage worked in it first use. If this therapy proves in, the Laser division will be selling a lot of systems and the DFOC is a one use product so each hospital maybe ordering several at a clip. I wonder what a hand made DFOC will cost and how many will be sold globally in say five years time. Put that in your rev model.

      Apr 06, 2017 06:36 AM

      Yeah, that’s quite amazing that the DFOC cage is 1/use.
      Would love to know if the other 2 are treated.

    Apr 06, 2017 06:03 AM

    I’m actually interested in knowing if he’d ever consider bringing in a new CEO with vast experience bringing drugs/tech through human trials in Canada.

    Maybe split the company into the therapeutic division and cancer division.

    Perhaps an awkward conversation to have but it’s something I think about quite a bit as a shareholder with over 100,000 shares. 🙂

    Apr 06, 2017 06:29 AM

    Al please ask when the two patients will start treatment. Very good news though.

    Thanks Charles